Roche (company)
Fenebrutinib Shows Promising Results in Relapsing Multiple Sclerosis Treatment
Fenebrutinib, Relapsing Multiple Sclerosis, BTK Inhibitor, Roche, Clinical Trials
Roche’s Fenebrutinib Shows Promising Results in Relapsing Multiple Sclerosis Phase II Trial
Roche, fenebrutinib, relapsing multiple sclerosis, BTK inhibitor, Phase II trial, FENopta study
Roche’s PiaSky Receives European Approval for Rare Blood Disorder Treatment
Roche, PiaSky, Crovalimab, Paroxysmal Nocturnal Hemoglobinuria (PNH), Rare Blood Disorder, European Approval
BioMarin Appoints Industry Veterans from Amgen and Roche in Executive Revamp
BioMarin, executive restructuring, Amgen, Roche, Greg Friberg, James Sabry, Roctavian, hemophilia A gene therapy
Genentech Closes Cancer Immunology Unit as Part of Broader R&D Restructuring
Genentech, Cancer Immunology, R&D Reprioritization, Roche, Cancer Research, Molecular Oncology
Sangamo Secures $50M Upfront in Neurodegenerative Pact with Roche’s Genentech
Sangamo, Roche, Genentech, neurodegenerative, biotech, licensing deal, milestone payments, biobucks
Roche Accelerates Obesity Drug Development and Explores M&A Opportunities
Roche, obesity drugs, M&A, pharmaceuticals, drug development
Roche Continues to Reap Rewards of Carmot Buyout with Strong Early GLP-1 Data
Roche, Carmot Therapeutics, GLP-1/GIP receptor agonist, CT-388, obesity treatment, weight loss, diabetes, pharmaceutical industry
Roche’s TIGIT Drug Tiragolumab Fails Another Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, Phase 3 trial, failure, Keytruda, Tecentriq
AbbVie’s Epkinly Enters Follicular Lymphoma Market, Competing with Roche’s Lunsumio
Epkinly, Lunsumio, follicular lymphoma, bispecific antibodies, AbbVie, Roche, FDA approval, cancer treatment